Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

venous thromboembolism

- PMLiVE

FDA approves Janssen’s Yondelis

Provides additional treatment option for softtissue sarcoma

EU flag

CHMP October meeting gives recommendations for Pfizer and MSD

But the regulatory advisors sound note ofcaution on Biogen’s Tecfidera

- PMLiVE

Bayer restructures its operations, drops Bayer Healthcare group

Will instead have divisions for pharmaceuticals, consumer health and crop science

- PMLiVE

Blue Latitude retains Janssen contract

Strategic marketing consultancy will continue tosupport the firm's EMEA brand teams

- PMLiVE

Janssen launches Stelara in the UK for adolescents

Psoriasis drug now available for younger patients

- PMLiVE

Imbruvica filed as first-line leukaemia therapy

Study shows improved progression-free survival

- PMLiVE

Taking a strategic approach

Janssen's Cyril Titeux on responding to the industry's pricing, access and reputational challenges

- PMLiVE

Janssen’s myeloma drug wins FDA priority review

Monotherapy daratumumab to be reviewed within six months

Bayer symbol

Bayer moves heart failure candidate finerenone into phase III

Follows positive phase IIb data presented at the European Society of Cardiology(ESC) meeting

- PMLiVE

J&J buys into Alligator’s immuno-oncology candidate

Will spend $700m on the early-stage cancer deal

Roche Basel Switzerland

Roche and AbbVie’s leukaemia drug set for filing by year-end

Blood cancer treatment venetoclax faces a tough market if approved

Daiichi Sankyo logo

Daiichi’s new anticoagulant recommended by NICE

Lixiana nears NHS funding approval for certain patients with atrial fibrillation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links